Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma

AIMS: To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. METHODS: Twelve patients with non‐Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open‐label, fixed‐sequence study. Patients received a sing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Br J Clin Pharmacol
Hauptverfasser: Agarwal, Suresh K., Salem, Ahmed Hamed, Danilov, Alexey V., Hu, Beibei, Puvvada, Soham, Gutierrez, Martin, Chien, David, Lewis, Lionel D., Wong, Shekman L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Drug Interactions
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5346863/
https://ncbi.nlm.nih.gov/pubmed/27859472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13175
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge